8-K: Harrow Inc. Reports Strong Q3 Revenue Growth, Anticipates Record-Breaking Finish to 2024

Harrow Inc. announced a 44% year-over-year revenue increase for the third quarter of 2024, driven by strong demand for key products and strategic market initiatives.

Summary

• Harrow Inc. reported a 44% increase in revenue for the third quarter of 2024, reaching $49.3 million compared to $34.3 million in the same period last year.
• The company experienced a GAAP net loss of $4.2 million, but achieved an adjusted EBITDA of $8.8 million.
• Operating cash flow for the quarter was $3 million, and the company held $72.6 million in cash and cash equivalents as of September 30, 2024.
• VEVYE prescriptions increased by 55% compared to the second quarter of 2024, while IHEEZO customer unit demand volume rose by 15% over the same period.
• The company is relaunching TRIESENCE in October 2024 and expects significant revenue contribution from this product in the fourth quarter.
• Harrow reaffirmed its 2024 revenue guidance of greater than $180 million, anticipating a strong fourth quarter to exceed this target.
• The company made a $37 million milestone payment for TRIESENCE in October 2024, funded by a $30 million draw from its credit facility and cash on hand.
• Gross margins improved to 76% in the third quarter of 2024, up from 71% in the same period of 2023, with core gross margins reaching 80%.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, increased prescription volumes, and a confident outlook for the future. While there are some operational challenges, the overall tone is optimistic and forward-looking.

Positives

• Harrow achieved a substantial 44% year-over-year revenue growth in the third quarter.
• The company's core gross margin improved to 80%, indicating better profitability.
• VEVYE's prescription volume increased significantly, demonstrating strong market acceptance.
• IHEEZO's customer unit demand also saw a notable increase, showing positive market traction.
• The relaunch of TRIESENCE is underway, expected to contribute significantly to future revenue.
• Harrow secured a major Medicare Part D win for VEVYE, expanding patient access.
• The company's cash flow from operations is improving, validating investments in sales and marketing.
• Harrow is implementing programs to reduce value leakage and improve its share of per unit revenue.
• The company is seeing strong performance in the fourth quarter, traditionally its strongest.

Negatives

• Harrow experienced a GAAP net loss of $4.2 million in the third quarter.
• The company faced a temporary inventory shortage of VEVYE in September, limiting revenue potential.
• A strategic pivot with IHEEZO at the end of the summer somewhat muted IHEEZO volumes.
• ZERVIATE sales were impacted by an out-of-stock issue due to a CDMO transition.
• The company missed some internal projections due to operational issues and strategic decisions.

Risks

• The company faces risks related to liquidity and results of operations.
• There are risks associated with implementing the business plan, developing and commercializing products, and managing pharmacy operations.
• Harrow faces competition from other pharmaceutical companies and pharmacies.
• General economic and business conditions, including inflation and supply chain challenges, pose risks.
• Regulatory and legal risks related to pharmacy operations and the pharmaceutical business are present.
• There are risks related to physician interest in and market acceptance of the company's products.
• The company's ability to service its debt and obtain necessary financing is a risk factor.
• The company is exposed to risks related to the Inflation Reduction Act and pharmaceutical regulatory policies.

Future Outlook

Harrow expects a record-breaking fourth quarter to close out a transformative 2024, with revenue significantly outpacing the third quarter. The company plans to provide 2025 revenue guidance after evaluating recent initiatives and the potential impact of the Inflation Reduction Act and new pharmaceutical regulatory policies.

Management Comments

• We are pleased with our progress in the third quarter of 2024, said Mark L. Baum, Chief Executive Officer of Harrow.
• Our expected revenue overperformance in the second half of 2024 versus the first half remains intact, as are our longer-term growth plans.
• We are seeing strong performance thus far in the fourth quarter, traditionally our strongest, for what we expect to be a record-breaking finish to a truly transformative year for Harrow.
• Harrow stockholders have much to be cheerful about as we report on the third quarter and work deeper into the fourth quarter, typically our strongest period of the year, and a statement buttressed by what looks like record October financial performance.
• I take responsibility for these shortcomings, which are non-terminal bumps as we pursue our more audacious and achievable longer-term financial goals.
• Based on what we are working on now and our initial forecasting, I remain confident that 2025 will be an operationally exciting and financially record-breaking year.

Industry Context

Harrow's performance is set against a backdrop of increasing awareness and demand for dry eye disease treatments, with competitors also investing in direct-to-consumer advertising. The company's focus on market access and affordability aligns with broader industry trends aimed at making medications more accessible to patients. The company is also navigating the complexities of the pharmaceutical industry, including middleman fees and regulatory changes.

Comparison to Industry Standards

• Harrow's 44% revenue growth significantly outpaces the average growth rate of many established pharmaceutical companies, which typically see single-digit or low double-digit growth.
• The 55% increase in VEVYE prescriptions is a strong indicator of market acceptance, especially when compared to the launch trajectories of other dry eye disease treatments, such as TYRVAYA, CEQUA, and MIEBO, which have shown more volatile growth patterns.
• Harrow's core gross margin of 80% is competitive with industry leaders, indicating efficient cost management and pricing strategies.
• The company's focus on reducing value leakage through partnerships with GoodRx and Asembia is a strategic move to improve profitability, which is a common challenge in the pharmaceutical industry.
• Harrow's strategic pivot with IHEEZO to focus on retina specialists is a targeted approach to capture a larger share of the intravitreal injection market, which is a high-volume segment within ophthalmology.

Stakeholder Impact

• Shareholders are expected to benefit from the company's strong revenue growth and positive outlook.
• Employees are recognized for their hard work and contribution to the company's success.
• Customers (eyecare professionals and patients) will benefit from increased access to and affordability of Harrow's products.
• Suppliers will benefit from the company's continued growth and demand for its products.
• Creditors will be reassured by the company's improved financial performance and cash flow.

Next Steps

• Harrow will continue to work on securing the TRIESENCE supply chain.
• The company will continue to expand its presence and accelerate VEVYE's market share.
• Harrow will bring on new IHEEZO group purchasing organization (GPO) distribution relationships.
• The company will continue to review new technologies and opportunities to manage prices and decrease cost structures.
• Harrow will provide 2025 revenue guidance after evaluating recent initiatives and the potential impact of the Inflation Reduction Act and new pharmaceutical regulatory policies.

Key Dates

Keywords

ophthalmic pharmaceuticals, eyecare, VEVYE, IHEEZO, TRIESENCE, revenue growth, EBITDA, prescription volume, market access, Medicare Part D